source
- FDA proposes new rare disease framework to accelerate therapy developmentDuring a public hearing, FDA officials outlined a newly proposed rare disease framework aimed at creating a lasting regulatory scheme. The initiative seeks to speed the development of safe and eff…
- Biogen CEO says early-stage R&D now a priority after record five INDs this yearBiogen's chief executive Chris Viehbacher told analysts that the company has shifted its strategy toward early-stage research and development. He highlighted that Biogen has filed five investigati…